Jpmorgan Chase & CO Agenus Inc Transaction History

Jpmorgan Chase & CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.53 - $0.93 $51,570 - $90,490	-97,302 Reduced 38.6%	154,778 $89,000
Q4 2023 Feb 12, 2024	BUY	$0.63 - $1.14 $8,120 - $14,694	12,890 Added 5.39%	252,080 $209,000
Q3 2023 Nov 14, 2023	SELL	$1.12 - $1.88 $35,609 - $59,772	-31,794 Reduced 11.73%	239,190 $270,000
Q2 2023 Aug 11, 2023	BUY	$1.31 - $2.04 $37,621 - $58,586	28,719 Added 11.85%	270,984 $433,000
Q1 2023 May 18, 2023	BUY	$1.45 - $2.95 $338,367 - $688,403	233,357 Added 2619.63%	242,265 $368,000
Q1 2023 May 11, 2023	SELL	$1.45 - $2.95 $250,906 - $510,465	-173,039 Reduced 95.1%	8,908 $13,000
Q4 2022 Feb 13, 2023	BUY	$2.02 - $3.25 $53,089 - $85,416	26,282 Added 16.88%	181,947 $436,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.14 $20,035 - $32,097	10,222 Added 7.03%	155,665 $319,000
Q2 2022 Aug 11, 2022	BUY	$1.3 - $2.64 $54,260 - $110,190	41,739 Added 40.25%	145,443 $282,000
Q1 2022 May 11, 2022	BUY	$2.35 - $3.47 $43,749 - $64,600	18,617 Added 21.88%	103,704 $255,000
Q4 2021 Feb 10, 2022	BUY	$2.92 - $5.74 $21,143 - $41,563	7,241 Added 9.3%	85,087 $274,000
Q3 2021 Nov 12, 2021	BUY	$4.98 - $6.63 $387,673 - $516,118	77,846 New	77,846 $409,000

2.07M

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.